Immunological Characteristics of Patients Receiving Ultra-Short Treatment for Chronic Hepatitis C.

ABSTRACT: Reducing the treatment duration for chronic hepatitis C could be an important tool in the effort to reach the elimination goals set by the World Health Organization. The current challenge is to predict the target group who will achieve sustained virological response at week 12 (SVR12) with shorter treatment duration. The aim of this exploratory study was to characterize immune subsets with focus on inhibitory receptors in patients who experienced SVR12 or virological relapse following four weeks treatment with glecaprevir/pibrentasvir with or without ribavirin. A total of 32 patients were included in this study of whom 21 achieved SVR12 and 11 had virological relapse. All available samples at baseline (n = 31) and end of treatment (EOT) (n = 30) were processed for flow cytometric analysis

SUBMITTER: Madsen LW 

PROVIDER: S-EPMC9271618 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature